A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides

This study has been completed.
Information provided by:
Johns Hopkins University
ClinicalTrials.gov Identifier:
First received: October 17, 2006
Last updated: January 9, 2009
Last verified: January 2009

October 17, 2006
January 9, 2009
April 2007
Not Provided
Intra-subject comparison of urine and plasma concentrations of 99mTc-DTPA [ Time Frame: 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours and 12-24 hours after introduction of the treatment assignment ]
Intra-subject comparison of urine and plasma concentrations of 99mTc-DTPA 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours and 12-24 hours after introduction of the treatment assignment.
Complete list of historical versions of study NCT00389311 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides
A Pilot Protocol to Determine the Effects of Chemical and Mechanical Stress on Rectal Permeability as a Surrogate for Toxicity Evaluation of Rectally Applied Microbicides

The purpose of this study is to determine if detectable changes in permeability of the lining of the colon are caused by either application of HIV microbicide gels or medical procedures, such as flexible sigmoidoscopy.

It is not currently known if procedures used to observe the lining of the distal colon, such as endoscopy with or without pinch biopsy, may cause mucosal trauma and thus alter colonic permeability. Additionally, the application of topical HIV microbicides (to prevent HIV transmission) and shearing forces associated with rectal intercourse might also adversely affect the epithelial layer, and thus alter colonic permeability. In order to appropriately interpret testing of the effects of topical HIV microbicides on the mucosal lining of the distal colon, it is essential to understand whether these procedures themselves, adversely affect the epithelial layer. If changes in permeability can be detected, this method may be developed to help determine microbicide distribution/toxicity in early phase studies, thus improving the selection of candidate microbicides for study in larger scale clinical trials.

Phase 0
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Diagnostic
HIV Infections
  • Drug: Normosol-R
  • Drug: Nonoxynol-9
  • Procedure: Gastrointestinal instrumentation
Not Provided
Fuchs EJ, Grohskopf LA, Lee LA, Bakshi RP, Hendrix CW. Quantitative assessment of altered rectal mucosal permeability due to rectally applied nonoxynol-9, biopsy, and simulated intercourse. J Infect Dis. 2013 May 1;207(9):1389-96. doi: 10.1093/infdis/jit030. Epub 2013 Jan 16.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  • Greater than or equal to 21 years of age
  • Prior history of receptive anal intercourse (RAI)
  • Subjects must have a history of using commercially-available personal lubricants for RAI.
  • Ability to provide signed informed consent.
  • Willingness to abstain from lubricant use and anal receptive intercourse for 48 hours prior to and 48 hours after Phases A and B.
  • Willingness to use a single dose of rectally-applied N-9.

Exclusion Criteria:

  • Mental handicap or impaired cognitive performance status as judged by the investigator.
  • Coagulation abnormality which would put the subject at risk for bleeding as judged by the Principal Investigator.
  • History of anorectal surgery within the last month or the presence of any anorectal disease or condition that in the judgment of the investigator could affect permeability of the rectal mucosa.
  • Presence of any painful anorectal conditions or anorectal lesions that would be tender to manipulation.
  • History of occupational radiation exposure.
  • History of acute or chronic diarrhea defined as three or more loose stools per day.
  • History of any allergic response to rectal lubricants.
  • History of sleep apnea, or airway problems with previous sedation procedures.
  • History of significant adverse reaction to sedation medications.
21 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
CDC 200-2001-08015-02
Not Provided
Not Provided
Johns Hopkins University
Not Provided
Principal Investigator: Edward Fuchs, PA-C, MBA The Johns Hopkins University
Johns Hopkins University
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP